The battle of Alzheimer's Disease - the beginning of the future unleashing the potential of academic discoveries

Frontiers in Pharmacology

Volumn 5 MAY, Issue , 2014, Pages

  Lundkvist, Johan ^a   Halldin, Magnus M ^a   Sandin, Johan ^a   Nordvall, Gunnar ^a   Forsell, Pontus ^a   Svensson, Samuel ^a   Jansson, Liselotte ^b   Johansson, Gunilla ^a   Winblad, Bengt ^a   Ekstrand, Jonas ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Alzheimerfonden   (Sweden)

Author keywords

Alzheimer's disease; Collaborative research; Drug discovery and development; Non profit; Pharmaceutical; Technology

Indexed keywords

AMYLOID BETA PROTEIN; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYLOIDOSIS; CLINICAL RESEARCH; DRUG IDENTIFICATION; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; HEALTH CARE COST; HUMAN; MEDICAL RESEARCH; NEUROPATHOLOGY; NON PROFIT ORGANIZATION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; SWEDEN;

EID: 84904702577     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00102     Document Type: Review

References (36)

1. Abbot, A. (2011). Novartis to shut brain research facility. Nature 480, 161-162.
2. Agis-Torres, A., Sölhuber, M., Fernandez, M., and Sanchez-Montero, J. M. (2014). Multi-target-directed ligands and other therapeutic strategies in the search of a real solution for Alzheimer's disease. Curr. Neuropharmacol. 12, 2-36. doi: 10.2174/1570159X113116660047
3. Alzheimer's Association. (2013). Alzheimer's Disease Facts and Figures. Chicago, IL: Alzheimer's Association. Available at: http://www.alz.org/alzheimers_disease_facts_and_figures.asp
4. Alzheimer's Drug Failure: implication for Future R&D in Neuroscience. (2012). Today's geriatric medicine. Available at: http://todaysgeriatricmedicine.com/news/081412_news.shtml
5. Ballenger, J. F. (2006). Progress in the history of Alzheimer's disease: the importance of context. J. Alzheimer's Dis. 9, 5-13.
6. Corbette, A., Pickett, J., Burns, A., Corcoran, J., Dunnett, S. B., Edison, P., et al. (2012). Drug repositioning for Alzheimer's disease. Nat. Rev. Drug Discov. 11, 833-846. doi: 10.1038/nrd3869
7. Cuatrecasas, P. (2006). Drug discovery in jeopardy. J. Clin. Invest. 116, 2837-2842. doi: 10.1172/JCI29999
8. Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., et al. (2014). Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370, 311-321. doi: 10.1056/NEJMoa1312889
9. Dunkel, P., Chai, C. L. L., Sperlagh, B., Hulett, P. B., and Matyus, P. (2012). Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis. Expert Opin. Invest. Drugs 21, 1267-1308. doi: 10.1517/13543784.2012.703178
10. Eriksdotter-Jönhagen, M., Linderoth, B., Lind, G., Aladellie, L., Almkvist, O., Andreasen, N. K., et al. (2012). Encapsulated cell biodelivery of nerve growth factor to the basal forebrain in patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 33, 18-28. doi: 10.1159/000336051
11. Francisa, P. T., Palmerb, A. M., Snapeb, M., and Wilcockc, G. K. (1999). The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry 66, 137-147. doi: 10.1136/jnnp.66.2.137
12. G8 Dementia Summit Agreements. (2013). Department of Health and Prime Minister's Office. London, UK. Available at: https://www.gov.uk/government/publications/g8-dementia-summit-agreements doi: 10.1016/S0140-6736(07)61487-1
13. Greenberg, B. D., Carrillo, M. C., Ryan, J. M., Gold, M., Gallagher, K., Grundman, M., et al. (2013). Improving Alzheimer's disease phase II clinical trials. Alzheimer's Demen. 9, 39-49. doi: 10.1016/j.jalz.2012.02.002
14. Hardy, J. (2006). A hundred years of Alzheimer's disease research. Neuron 52, 3-13. doi: 10.1016/j.neuron.2006.09.016
15. Herholz, K., and Ebmeier, K. (2011). Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol. 10, 667-670. doi: 10.1016/S1474-4422(11)70123-5
16. Kepp, K. K. (2012). Bioinorganic chemistry of Alzheimer's disease. Chem. Rev. 112, 5193-5239. doi: 10.1021/cr300009x
17. Kola, I., and Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715. doi: 10.1038/nrd1470
18. Lane, R. F., Shineman, D. W., Steele, J. W., Lee, L. H., and Fillit, H. M. (2012) Beyond amyloid: the future of therapeutics for Alzheimer's disease. Adv. Pharmacol. 64, 213-271. doi: 10.1016/B978-0-12-394816-8.00007-6
19. Lindvall, O., and Wahlberg, L. U. (2008). Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease? Exp. Neurol. 209, 82-88. doi: 10.1016/j.expneurol.20008.019
20. Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., and Kivipelto, M. (2010). Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 9, 702-716. doi: 10.1016/S1474-4422(10)70119-8
21. Misra, S., and Medhi, B. (2013). Drug development status for Alzheimer's disease: present scenario. Neurol. Sci. 34, 831-839. doi: 10.1007/s10072-013-1316-x
22. Munos, B. (2009). Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8, 959-968. doi: 10.1038/nrd2961
23. Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., et al. (2010). How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203-214. doi: 10.1038/nrd3078
24. Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., et al. (2014). Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370, 322-333. doi: 10.1056/NEJMoa1304839
25. Savonenko, A. V., Melnikova, T., Hiatt, A., Li, T., Worley, P. F., Troncoso, P. F., et al. (2012). Alzheimer's therapeutics: translation of preclinical science to clinical drug development. Neuropsychopharmacol. Rev. 37, 261-277. doi: 10.1038/npp.2011.211
26. Scannell, J. W., Blanckley, A., Boldon, H., and Warrington, B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11, 191-200. doi: 10.1038/nrd3681
27. Schachter, A. D., and Ramoni, M. F. (2007). Clinical forecasting in drug development. Nat. Rev. Drug Discov. 6, 107-108. doi: 10.1038/nrd2246
28. Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., et al. (2014). Alzheimer's disease clinical trials and late-stage drug development: a retrospective appraisal. J. Intern. Med. 275, 251-283. doi: 10.1111/joim.12191
29. Slusher, B. S., Conn, P. J., Frye, S., Glicksman, M., and Arkin, M. (2013). Bringing together the academic drug discovery community. Nat. Rev. Drug Discov. 12, 811-812. doi: 10.1038/nrd4155
30. Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., et al. (2011). Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 7, 280-292. doi: 10.1016/j.jalz.2011.03.003
31. The Dominantly Inherited Alzheimer Network (DIAN). St. Louis, MO: Washington University. Available at: http://www.dian-info.org/default.htm
32. U.S. Food and Drug Administration. (2013). Guidance for Industry: Alzheimer's Disease: Developing Drugs in the Treatment of Early Stage Disease. Rockville, MD: FDA.
33. World Alzheimer Report 2013. (2014). Alzheimer's Disease International. London, UK. Available at: http://www.alz.co.uk/research/world-report-2013
34. 75 Years of Mortality in the United States, 1935-2010. (2012). Centers for Disease Control and Prevention, National Center for Health Statistics. Hyattsville, MD. Available at: http://www.cdc.gov/nchs/data/databriefs/db88.htm
35. World Health Organization. (2012). Dementia Fact Sheet No. 362 April 2012. Available at: http://www.who.int/mediacentre/factsheets/fs362/en/
36. World Population Review. (2013). Available at: http://worldpopulationreview.com/continents/world-population/ (accessed March 15, 2014).